Prospective study on cost-effectiveness of home-based motor assessment in Parkinson’s disease
暂无分享,去创建一个
D. Heldman | E. Cubo | N. Mariscal | B. Solano | V. Becerra | D. Armesto | S. Calvo | J. Arribas | J. Seco | A. Martinez | L. Zorrilla | E Cubo | N Mariscal | B Solano | V Becerra | D Armesto | S Calvo | J Arribas | J Seco | A Martinez | L Zorrilla | D Heldman | A. Martínez
[1] Francesc Valldeoriola,et al. Prospective comparative study on cost‐effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.
[2] J. Giuffrida,et al. Objective motion sensor assessment highly correlated with scores of global levodopa-induced dyskinesia in Parkinson's disease. , 2013, Journal of Parkinson's disease.
[3] A. Stiggelbout,et al. Assessing comorbidity in patients with Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.
[4] R. García-Ramos,et al. The social impact of Parkinson's disease in Spain: Report by the Spanish Foundation for the Brain. , 2016, Neurologia.
[5] D. Heldman,et al. Clinician versus machine: reliability and responsiveness of motor endpoints in Parkinson's disease. , 2014, Parkinsonism & related disorders.
[6] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[7] Paolo Barone,et al. The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study , 2007, Movement disorders : official journal of the Movement Disorder Society.
[8] D. Heldman,et al. Feasibility of home-based automated Parkinson's disease motor assessment , 2012, Journal of Neuroscience Methods.
[9] K. Bötzel,et al. Costs of illness and care in Parkinson's Disease: An evaluation in six countries , 2011, European Neuropsychopharmacology.
[10] W. Gibb,et al. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.
[11] V. Calabrese,et al. PROJECTED NUMBER OF PEOPLE WITH PARKINSON DISEASE IN THE MOST POPULOUS NATIONS, 2005 THROUGH 2030 , 2007, Neurology.
[12] Laurent Gerbaud,et al. Impact of the motor complications of Parkinson's disease on the quality of life , 2005, Movement disorders : official journal of the Movement Disorder Society.
[13] S. Zarit,et al. Subjective burden of husbands and wives as caregivers: a longitudinal study. , 1986, The Gerontologist.
[14] M. Hoehn,et al. Parkinsonism , 1967, Neurology.
[15] C. Lundqvist,et al. Real life cost and quality of life associated with continuous intraduodenal levodopa infusion compared with oral treatment in Parkinson patients , 2014, Journal of Neurology.
[16] D. Revicki,et al. Methods and issues associated with the use of quality-adjusted life-years , 2012, Expert review of pharmacoeconomics & outcomes research.
[17] C. Clarke,et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[18] Robert Chen,et al. Differential response of speed, amplitude, and rhythm to dopaminergic medications in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[19] H. Birnbaum,et al. Pharmacoeconomics and health policy. Current applications and prospects for the future. , 1999, PharmacoEconomics.
[20] W. Oertel,et al. Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.
[21] Pablo Martinez-Martin,et al. A short Scale for Evaluation of Neuropsychiatric Disorders in Parkinson’s Disease: first psychometric approach , 2012, Journal of Neurology.
[22] Robert Chen,et al. The modified bradykinesia rating scale for Parkinson's disease: Reliability and comparison with kinematic measures , 2011, Movement disorders : official journal of the Movement Disorder Society.
[23] R. Dodel,et al. Assessing health-related quality of life in patients with Parkinson's disease in a prospective longitudinal study. , 2007, Parkinsonism & related disorders.
[24] M. Drummond,et al. Some guidelines on the use of cost effectiveness league tables. , 1993, BMJ.
[25] Diane C. Tsai. Recent Developments in Parkinson's Disease , 1986, The Yale Journal of Biology and Medicine.
[26] G. Huston. The Hospital Anxiety and Depression Scale. , 1987, The Journal of rheumatology.
[27] Carmen Rodriguez-Blazquez,et al. Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis , 2015, PloS one.
[28] H. Glick,et al. Preference-based quality-of-life in patients with Parkinson’s disease , 2002, Neurology.
[29] Sandeep Vijan,et al. The value of medical spending in the United States, 1960-2000. , 2006, The New England journal of medicine.
[30] Abraham Weizman,et al. Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease. , 1998, Clinical neuropharmacology.
[31] C. Tanner,et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 , 2007, Neurology.
[32] E. Cubo,et al. Comparison of office‐based versus home web‐based clinical assessments for Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.
[33] A. Hrõbjartsson,et al. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment , 2004, Journal of internal medicine.
[34] Joseph P. Giuffrida,et al. Clinically deployable Kinesia™ technology for automated tremor assessment , 2009, Movement disorders : official journal of the Movement Disorder Society.
[35] X. Badia,et al. [The Spanish version of EuroQol: a description and its applications. European Quality of Life scale]. , 1999, Medicina clinica.